This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. SABS, CRIS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHRShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Its Competitors SAB Biotherapeutics Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Cytori Therapeutics (NASDAQ:CYTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Is CYTX or SABS more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Cytori Therapeutics' net margin of -242.60%. SAB Biotherapeutics' return on equity of -153.92% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% SAB Biotherapeutics N/A -153.92%-89.16% Which has stronger earnings and valuation, CYTX or SABS? Cytori Therapeutics has higher revenue and earnings than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M2.98-$12.63MN/AN/ASAB Biotherapeutics$1.32M16.80-$34.10M-$4.00-0.53 Which has more risk and volatility, CYTX or SABS? Cytori Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CYTX or SABS? 2.6% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 0.7% of Cytori Therapeutics shares are owned by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate CYTX or SABS? SAB Biotherapeutics has a consensus target price of $11.00, indicating a potential upside of 416.43%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CYTX or SABS? In the previous week, SAB Biotherapeutics had 2 more articles in the media than Cytori Therapeutics. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Cytori Therapeutics. SAB Biotherapeutics' average media sentiment score of 0.22 beat Cytori Therapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cytori Therapeutics Neutral SAB Biotherapeutics Neutral SummarySAB Biotherapeutics beats Cytori Therapeutics on 10 of the 14 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.93M$72.80M$5.76B$10.03BDividend YieldN/AN/A5.28%4.52%P/E RatioN/A10.8175.4326.15Price / Sales2.9889.59515.98171.98Price / CashN/A18.4137.2059.76Price / Book1.4112.2811.536.20Net Income-$12.63M-$25.86M$3.28B$270.56M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$0.49+3.2%N/A-60.8%$10.93M$3.67M0.0037High Trading VolumeSABSSAB Biotherapeutics3.2043 of 5 stars$2.18+3.0%$11.00+403.9%-26.8%$22.55M$1.32M-0.54140Short Interest ↓CRISCuris1.8591 of 5 stars$1.68+0.3%$17.00+914.9%-63.4%$20.46M$10.91M-0.3460BOLTBolt Biotherapeutics3.3169 of 5 stars$4.93-4.0%$47.50+864.3%-60.2%$9.86M$7.69M-0.1990AMGNAmgen4.78 of 5 stars$285.50-0.5%$304.43+6.6%-14.1%$153.63B$34.92B23.3328,000Positive NewsGILDGilead Sciences4.9418 of 5 stars$112.680.0%$115.39+2.4%+46.2%$139.62B$28.75B22.4117,600Positive NewsVRTXVertex Pharmaceuticals4.9657 of 5 stars$400.44+2.4%$497.10+24.1%-15.8%$102.40B$11.02B28.556,100Positive NewsREGNRegeneron Pharmaceuticals4.7657 of 5 stars$585.69+1.3%$817.67+39.6%-51.4%$61.79B$14.20B14.6915,106Positive NewsALNYAlnylam Pharmaceuticals3.6557 of 5 stars$450.71+0.9%$412.79-8.4%+90.4%$58.81B$2.25B-181.652,230BIIBBiogen4.745 of 5 stars$143.56+2.8%$185.74+29.4%-27.9%$20.78B$10.00B13.557,605Positive NewsUTHRUnited Therapeutics4.534 of 5 stars$406.04+0.3%$412.69+1.6%+15.8%$18.44B$3.08B15.961,305Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies SABS Competitors CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTX Stock Alerts